Figure 4: Localization of MG53 to the surface membrane of A549 cells after treatment with anoxia and reoxygenation (A/R).
From: Treatment of acute lung injury by targeting MG53-mediated cell membrane repair
(a) Immunofluorescence staining of endogenous MG53 in A549 cells. Control cells show cytosolic distribution of MG53- and A/R-treated cells display membrane localization of MG53. (b) Top panels show FITC staining of endogenous MG53 in control cells (left), A/R-treated cells (middle and right). Bottom panels show Rhodamine-labelled rhMG53 added to control cells (left) and A/R-treated cells (middle), or Rhodamine-labelled BSA added to A/R-treated A549 cells (right). (c) Left panels show FITC-labelling of Annexin V in A/R-treated A549 cells following incubation with rhMG53 (top) or BSA as control (bottom). Middle panels show Rhodamine-labelling of rhMG53 (top) or lack of Rhodamine-labelling of BSA (bottom) in A/R-treated A549 cells. Right panels show colocalization of Annexin V and rhMG53 (top) and lack of colocalization between Annexin V and BSA (bottom) in A/R-treated A549 cells. The images shown were representative of >104 cells in at least four separate experiments.
